Emory University Myovant Sciences Ltd. Transaction History

Emory University

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 13, 2020	SELL	$4.2 - $19.21 $615,195 - $2.81 Million	-146,475 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$5.19 - $9.46 $163,552 - $298,112	-31,513 Reduced 17.71%	146,475 $762,000
Q2 2019 Aug 14, 2019	BUY	$8.69 - $25.0 $574,087 - $1.65 Million	66,063 Added 59.02%	177,988 $1.61 Million
Q1 2019 May 09, 2019	SELL	$16.83 - $24.45 $205,763 - $298,925	-12,226 Reduced 9.85%	111,925 $2.67 Million
Q4 2018 Feb 12, 2019	BUY	$15.01 - $25.2 $1.86 Million - $3.13 Million	124,151 New	124,151 $2.04 Million

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Emory University, based on Form 13F filings with the SEC.

Stay updated on Emory University with notifications on news.